CD38 and neoplasm: Non-clinical studies evaluating the activity of a murine cross-reactive surrogate of modakafusp alfa (anti-murine CD38 AttenukineTM; mCD38-mAtt) in a non-CD38-expressing, mildly IFNα-sensitive CT26 tumor model in immunocompetent mice showed significant antitumor activity posttreatment with mCD38-mAtt versus a non-targeted control, as well as increased CD8 T-cell proliferation (17).